- Europe market = USD $990mil- US market = USD $2bil.- China...

- Europe market = USD $990mil
- US market = USD $2bil.
- China market = USD $2.8bil.
- Japan+ rest of Asia = USD $1.2bil?

- EU+Canada+Aus market deal = AUD $10.8mil upfront payment + AUD $219mil milestone payments + 15%-20% royalties on sales (this is imassive annual income for DXB)

So, one would anticipate:

- US market deal = AUD $20mil upfront payment + $420mil milestone payment + 15%-20% royalties on annual sales.

- China market = similar deal structure as US market.

- Japan and Asia = similar deal structure as EU deal.

All up, we are looking at a potential total upfront payment of around $50mil-$60mil, and total milestone payments of $1.2bil, and 15%-20% annual royalties on global sales which is massive annual income to DXB.

I like the fact that DMX-200 is in phase 3 clinical study, not phase 1, not phase 2.

I also like the fact that the DXB has been very confident with this phase 3 results that it has been able to sign a distribution deal with Advanz in advance and has been active in marketing preparation of the product with a name registered and approved by FDA. DMX-200 is now registered and will be marketed as QYTOVRA.

Obviously ADVANZ PHARMA must be very confident of QYTOVRA product that it wants to lock in this distribution deal (and I think it is very very substantial deal for DXB given its MC is only $69mil right now). The key piece of info here is: $10.8mil as upfront payment to DXB. ADVANZ PHARMA wouldn't throw $11mil away like that if they are not close to 100% sure the phase 3 result is good.

I also like the fact that management is very confident of DMX-200 result that they are already working on commercial scale manufacturing arrangements for the product.





Will it beat NEU.asx in terms of MC? I think it has a chance.


I like it and I am in.